Megan Hollasch

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication OncologyLive, aiding in all aspects of the publication process, as well as content for OncLive.com.

Articles

Novel Prompt Shows Potential to Decrease Overtreatment in Older Patients With Early-Stage Breast Cancer

July 24th 2024

An EHR-based prompt or “nudge” decreased the rates of sentinel lymph node biopsy among older patients with early-stage breast cancer.

Tucatinib Retains its Role in HER2+ Metastatic Breast Cancer, Prompting Questions of T-DXd’s Potential Takeover in the First Line

July 24th 2024

Adrienne G. Waks, MD, details her approach to treatment sequencing in metastatic HER2-positive disease and the potential role of T-DXd in the first line.

Neoadjuvant Therapy Selection: Are Abbreviated Regimens an Option in HER2+ Breast Cancer?

July 23rd 2024

Adrienne G. Waks, MD, parses out recent and upcoming data in HER2+ breast cancer and discusses why abbreviated neoadjuvant regimens are not ready for primetime.

KIM-1 Demonstrates Potential Utility as a Biomarker With Worse DFS Outcomes in KIM-1–High RCC

July 21st 2024

Brian Rini, MD, details recent data in renal cell carcinoma surrounding the utility of KIM-1 as a potential biomarker and next steps for KIM-1 research.

Complexity in GI Cancer: Questions Are Answered in Gastroesophageal Cancer, Remain in HCC

July 19th 2024

Tanios S. Bekaii-Saab, MD, FACP, details data from the ESOPEC trial in early-stage gastroesophageal cancers, and findings from Checkmate-9DW in HCC.

Longest OS Reported From a Third-Line mCRC Randomized Trial Is Seen in ARC-9 Study

July 18th 2024

Tanios S. Bekaii-Saab, MD, highlights data from the phase 1/2 ARC-9 study which showed promising overall survival data in patients with colorectal cancer.

Sequencing of Bispecific Antibodies vs CAR T-Cell Therapies is Dependent on Several Factors in DLBCL, Multiple Myeloma

July 17th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses selection and sequencing considerations for bispecific antibodies and CAR T-cell therapies in DLBCL.

ASCO 2024 Data Shake Up Standards and Shed Light on Biomarkers

July 16th 2024

This roundup includes exclusive insights from nearly 20 clinicians and key data on the top abstracts coming out of the 2024 ASCO Annual Meeting.

CAR T-Cell Therapy Selection in Follicular Lymphoma Requires Careful Consideration

July 15th 2024

Francisco Hernandez-Ilizaliturri, MD, details factors that influence CAR T-cell therapy selection in relapsed/refractory follicular lymphoma.

Epcoritamab Shines in Third-Line Follicular Lymphoma With the Potential to Move into Earlier Lines

July 12th 2024

Grzegorz S. Nowakowski, MD, discusses the accelerated approval of epcoritamab in follicular lymphoma, touching on key trial data and remaining unmet needs.

Dual Targeting of the mTOR Pathway May Enhance Antitumor Activity in Solid Malignancies

July 11th 2024

Recent studies of novel mTOR inhibitors in combination with various agents have shown how these combinations may be used for patients with solid tumors.

Locoregional Therapy With Combination Regimens Including TACE Generate Excitement in HCC

July 5th 2024

Anjana Pillai, MD, detailed how the treatment landscape for HCC is evolving, highlighting data from EMERALD-1.

The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors

July 5th 2024

S. Lindsey Davis, MD, highlights data with the mTOR inhibitor sapanisertib and Aurora A kinase inhibitor alisertib in patients with solid tumors.

TARE Gains Traction as Suitable Alternative to TACE for Locoregional HCC Therapy

July 3rd 2024

Anjana Pillai, MD, details a patient case study and key takeaways from a presentation she gave at an OncLive® State of the Science Summit™ on locoregional therapies for HCC.

Dual mTORC1/mTORC2 Inhibitor Sapanisertib Shows Promise in Combination Regimens for Solid Tumors

July 2nd 2024

Vivek Subbiah, MD, details the rationale for combining sapanisertib with ziv-aflibercept or metformin and next steps for mTOR inhibitors in solid tumors.

Lutetium Lu 177 Dotatate Enters the Pediatric Treatment Paradigm for SSTR+ GEP-NETs

June 27th 2024

Daniel M. Halperin, MD, details the FDA approval of lutetium Lu 177 dotatate as well as safety and efficacy data in pediatric and adult patients treated with the agent.

Effects of Cancer Drug Shortages Linger as New Survey Results Show Impacts on Clinical Trials

June 26th 2024

Eighty-nine percent of cancer centers are experiencing shortages of at least 1 systemic therapy, impacting clinical trials at 43% of centers.

Addressing the Logistics of At-Home Cancer Care With Subcutaneous Administration of Immunotherapy

June 25th 2024

Jorge J. Nieva, MD, details the role of telemedicine for patients with non–small cell lung cancer and a first-of-its-kind study examining atezolizumab given subcutaneously at home.

CD19-Directed CAR T-Cell Therapy Demonstrates Clinical Efficacy in Richter Transformation

June 16th 2024

Treatment with FDA-approved CAR T-cell therapies for non-Hodgkin lymphoma was efficacious and feasible in patients with Richter transformation.

Disease Duration, Elevated WBC Count, and VAF Predict Disease Progression in Polycythemia Vera

June 14th 2024

Time from diagnosis, elevated WBC count, and VAF were all significantly associated with an increased risk of disease progression of polycythemia vera.